PMC:7200337 / 110780-113370 JSONTXT

Annnotations TAB JSON ListView MergeView

2_test

Id Subject Object Predicate Lexical cue
32505227-29242543-46575472 1219-1223 29242543 denotes 2018
32505227-32273594-46575473 1443-1447 32273594 denotes 2020
32505227-32092539-46575474 1456-1460 32092539 denotes 2020
32505227-32273591-46575475 1971-1975 32273591 denotes 2020
T10568 1219-1223 29242543 denotes 2018
T15705 1443-1447 32273594 denotes 2020
T77217 1456-1460 32092539 denotes 2020
T35247 1971-1975 32273591 denotes 2020

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T60 1043-1047 Body_part denotes body http://purl.org/sig/ont/fma/fma256135
T61 1285-1293 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T103 1713-1718 Body_part denotes scale http://purl.obolibrary.org/obo/UBERON_0002542

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T632 57-65 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T633 68-77 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T634 239-247 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T635 383-391 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T636 484-492 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T637 805-813 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T638 958-966 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T639 1319-1327 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T640 1391-1399 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T641 2027-2035 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T642 2434-2442 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T121 28-29 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T122 78-81 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T123 170-177 http://purl.obolibrary.org/obo/UBERON_0000473 denotes testing
T124 338-339 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T125 414-417 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T126 500-501 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T127 518-519 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T128 1219-1223 http://purl.obolibrary.org/obo/CLO_0001185 denotes 2018
T129 1356-1362 http://purl.obolibrary.org/obo/NCBITaxon_33208 denotes animal
T130 1668-1669 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T131 1926-1927 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T132 2100-2107 http://purl.obolibrary.org/obo/UBERON_0000473 denotes testing
T133 2328-2329 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T134 2483-2488 http://purl.obolibrary.org/obo/CLO_0001658 denotes ACTIV

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T4566 1847-1851 Chemical denotes cGMP http://purl.obolibrary.org/obo/CHEBI_16356

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T11 1175-1180 http://purl.obolibrary.org/obo/GO_0007568 denotes aging
T12 1566-1582 http://purl.obolibrary.org/obo/GO_0006955 denotes immune responses

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
3640 2564-2566 Gene denotes to Gene:6999
3641 2502-2504 Gene denotes to Gene:6999
3642 2238-2240 Gene denotes to Gene:6999
3643 2162-2164 Gene denotes to Gene:6999
3644 2083-2085 Gene denotes to Gene:6999
3645 2071-2073 Gene denotes to Gene:6999
3646 1987-1989 Gene denotes to Gene:6999
3647 1923-1925 Gene denotes to Gene:6999
3648 1799-1801 Gene denotes to Gene:6999
3649 1064-1066 Gene denotes to Gene:6999
3650 854-856 Gene denotes to Gene:6999
3651 775-777 Gene denotes to Gene:6999
3652 759-761 Gene denotes to Gene:6999
3653 651-653 Gene denotes to Gene:6999
3654 38-40 Gene denotes to Gene:6999
3655 239-247 Species denotes SARS-CoV Tax:694009
3656 312-320 Species denotes MERS-CoV Tax:1335626
3657 383-393 Species denotes SARS-CoV-2 Tax:2697049
3658 1400-1408 Species denotes patients Tax:9606
3659 2314-2322 Species denotes patients Tax:9606
3660 2387-2399 Species denotes participants Tax:9606
3661 1847-1851 Chemical denotes cGMP
3662 57-77 Disease denotes SARS-CoV-2 infection MESH:C000657245
3663 484-492 Disease denotes COVID-19 MESH:C000657245
3664 805-813 Disease denotes COVID-19 MESH:C000657245
3665 958-966 Disease denotes COVID-19 MESH:C000657245
3666 1319-1327 Disease denotes COVID-19 MESH:C000657245
3667 1391-1399 Disease denotes COVID-19 MESH:C000657245
3668 2027-2035 Disease denotes COVID-19 MESH:C000657245
3669 2434-2442 Disease denotes COVID-19 MESH:C000657245

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T661 0-205 Sentence denotes Although the development of a vaccine to protect against SARS-CoV-2 infection has progressed at an unprecedented rate and produced an impressive volume of candidates for testing, many challenges lie ahead.
T662 206-511 Sentence denotes The prior knowledge gained after SARS-CoV-1 was first discovered in 2003, and the subsequent emergence of MERS-CoV in 2012 provided a significant jumpstart, but the progress of SARS-CoV-2 vaccine development has already far outstripped the point of the blueprint created before COVID-19 became a pandemic.
T663 512-709 Sentence denotes While a variety of platforms are simultaneously being innovated or adapted, they each have strengths and limitations, many of which relate to the delicate balance between safety and immunogenicity.
T664 710-870 Sentence denotes Many shortcuts have been taken and will continue to be taken due to the urgency of the ongoing COVID-19 pandemic, but significant concerns need to be addressed.
T665 871-1012 Sentence denotes One such concern involves the accumulating data supporting the initial assessment that COVID-19 is disproportionately severe in older adults.
T666 1013-1225 Sentence denotes In conjunction with the large body of work related to immune senescence, these findings indicate that vaccine design should take into consideration the impact of aging on vaccine efficacy (Nikolich-Žugich, 2018).
T667 1226-1503 Sentence denotes Furthermore, questions remain regarding the possibility of antibody-dependent enhancement of COVID-19, with in vitro experiments, animal studies, and two studies of COVID-19 patients supporting this possibility (Cao, 2020, Tetro, 2020, Zhang et al., 2020a, Zhao et al., 2020a).
T668 1504-1678 Sentence denotes Assuming vaccine candidates that can safely induce protective immune responses are identified, additional major hurdles will be the production and dissemination of a vaccine.
T669 1679-1977 Sentence denotes For some types of vaccines, large-scale production will not be as much of an issue, and infrastructure already in place to produce current Good Manufacturing Practice (cGMP)-quality biologics can be repurposed, but this will only be applicable to a subset of the candidates (Thanh Le et al., 2020).
T670 1978-2400 Sentence denotes In order to address the urgent need and stem the COVID-19 pandemic, regulatory agencies need to continue to support rapid testing and progression of vaccine candidates, companies need to disseminate important findings directly and openly, and researchers need to investigate correlates of protection using in-depth immune monitoring of patients with a broad range of clinical presentations and clinical trial participants.
T671 2401-2590 Sentence denotes The newly announced Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) is designed to bring together numerous governmental and industry entities to help address this need.